Navigation Links
Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
Date:3/25/2008

tients required rescue medication relative to placebo. Evaluations in other dose groups favored Adlea over placebo. Adlea was well tolerated in these studies and adverse events were comparable for placebo and Adlea treated patients.

How Adlea May Address the Need for Long-Duration, Well-Tolerated Pain Relief

Adlea is a long-acting, non-opioid drug with the potential to provide pain relief for weeks to months after just a single localized treatment. Its novel mechanism of action results in site-specific efficacy intended to avoid the unwanted side effects associated with systemically administered analagesic drugs.

Adlea is a highly purified form of capsaicin (derived from chili peppers) that acts on C nerve fibers, which transmit long-term pain, by binding to and desensitizing the TRPV1 pain receptors. This leads to a prolonged, reversible and localized desensitization of the pain fibers. The drug generally has a short half-life of 1 to 2 hours. It is undetectable in blood sample analyses after 24 hours.

Adlea's short duration of systemic exposure (hours) relative to the long duration of analgesia (weeks to months) may offer a safe, additive treatment option in the management of post-surgical orthopedic pain. Importantly, the prolonged analgesic effect resulting from localized administration of Adlea does not seem to be associated with the systemic side effects commonly associated with opioids (respiratory depression, nausea/vomiting, sedation, disorientation, physical dependence, and the risk of addiction), or with NSAIDs (gastrointestinal and renal toxicities, and impaired clotting) or COX-2 inhibitors (cardiovascular risks and renal toxicity).

Adlea is also in clinical development for the treatment of pain associated with moderate to severe osteoarthritis. In an exploratory trial in this setting, Adlea provided sustained pain reduction as compared to baseline over the twelve week study period.

About Anesiva and its Diverse
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
2. Anesiva Defines Regulatory Pathway for Adlea with FDA
3. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
4. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
5. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
9. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
10. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
11. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015 NorthStar Anesthesia , one ... it has been selected by Mercy, based in ... four of their hospitals:  Mercy St. Vincent  Medical Center and ... , Mercy St. Charles  Hospital in Oregon ... Tiffin . "As we looked to ...
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ ... announced the issuance of a white paper on the ... spray product.  The white paper was presented to the ... by Dr. James H. Anderson, Jr. , MD, ... be viewed online on the Generex website. ...
(Date:8/27/2015)...  BioElectronics Corporation (OTC Pink: BIEL), the maker of ... featuring the use of ActiPatch®, its novel musculoskeletal pain ... Congress of the European Pain Federation EFIC®, ... The Company will also be exhibiting at the Congress ... , department clinical and experimental rheumatology from the University ...
Breaking Medicine Technology:Four Mercy Hospitals in Northwest Ohio Select NorthStar Anesthesia 2Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2
... BURLINGTON, Mass., Dec. 7, 2010 ... cardiovascular diagnostic imaging technologies, today announced the publication of ... association of stent thrombosis with lipid core plaque as ... is the first and only FDA-approved system to provide ...
... 2010 Cymetrix, a leader in providing healthcare ... announced an alliance with Siemens Healthcare for financial ... partnership, Cymetrix will assist in the transition of ... systems to Siemens Soarian®. Cymetrix,s system conversion solution ...
Cached Medicine Technology:InfraReDx Announces Publication of a Case Report in Circulation Highlighting Novel Clinical Finding with LipiScan™ Coronary Imaging System 2Cymetrix Forms Alliance With Siemens Healthcare for System Conversion Support 2
(Date:8/28/2015)... Beach, FL. (PRWEB) , ... August 28, 2015 ... ... problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach ... believes that it should begin with the employer and employees getting together for ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... patient loyalty at a low cost. Personalized with practice contact information and logos, ... patients. Dental offices can also incorporate Calendars into seasonal mailings, thank you and ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics ... to go deep sea diving. The act of recreational diving exposes the ... these reasons, it is vital that all recreational and professional divers undergo regular ...
(Date:8/28/2015)... ... 28, 2015 , ... Popular review site Top5MillionaireDatingSites.com recently published ... . According to the listings, MillionaireMatch.com bags the top spot while ... spokesperson of Top5MillionaireDatingSites.com said, “This website has been designed to assist ...
(Date:8/28/2015)... ... August 28, 2015 , ... Inc. magazine today ranked PREVENT Life Safety ... the nation’s fastest-growing private companies. The list was unveiled online at Inc.com and is ... the last three years, PREVENT ranks higher on the list than any other company ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... the gold standard for detecting colon cancer. But many patients ... invasive test.// Recently, a fecal occult blood stool test has ... stool. However, the test misses a majority of cancers. The ... say the results are encouraging. ,“A simple, non-invasive test ...
... unknown origin are the eighth leading type of cancers. ... Profiling // may now help identify where tumors first ... about 86-percent accurate in determining a tumor’s origin. ... tumor type. Giving the wrong treatment may slow recovery ...
... change in body position may increase an individual’s chances of ... recent study . ,The research is based on a ... or a transient ischemic attack (TIA), also known as a ... common, occur when blood flow to the brain is reduced. ...
... treatment with the oral drug bosentan (Tracleer) has led ... arterial hypertension ( PAH) // . ,PAH is ... is believed to cause the overproduction of endothelin, which ... obstructed. This chronic obstruction leads to PAH, a condition ...
... shows a diet rich in omega-3 and omega-6 fatty acids may ... Researchers say they studied mice to determine the effects of a ... animals were divided into four groups. The first received a diet ... a diet rich in omega-6 fatty acids along with the drug ...
... According to latest research patients who were treated for ... of vitamin B12 in their blood.// An increasing amount ... B and depression, but the specifics have not been ... relationship of vitamin B12 and the treatment of depression. ...
Cached Medicine News:
Inquire...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Multi-Tier Shaker...
... shake up to 16 of AutoGen's tube units ... This new system is most appropriate for bacterial ... digestion. Now you can further simplify your ... our AutoIncubator 96 and then placing our 6-hole ...
Medicine Products: